Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease.
OBJECTIVE
Observational studies have suggested that Helicobacter pylori may protect against gastrointestinal reflux disease (GERD), but these results could be due to bias or confounding factors. We addressed this in a prospective, double blind, randomized, controlled trial.


METHODS
H. pylori-positive patients with at least a 1-year history of heartburn with a normal endoscopy or grade A esophagitis were recruited. Patients were randomized to 20 mg omeprazole, 250 mg clarithromycin, and 500 mg tinidazole twice a day for 1 week or 20 mg omeprazole twice a day and identical placebos. A second concurrently recruited control group of H. pylori-negative patients were given open label 20 mg omeprazole twice a day for 1 week. All patients received 20 mg omeprazole twice a day for the following 3 weeks and 20 mg omeprazole once daily for a further 4 weeks. Omeprazole was discontinued at 8 weeks and patients were followed up for a further 10 months. A relapse was defined as moderate or severe reflux symptoms. H. pylori eradication was determined by 13C-urea breath test.


RESULTS
The H. pylori-positive cases were randomized to antibiotics (n = 93) or placebo (n = 97). Relapse of GERD occurred in 83% of each of the antibiotic, placebo, and H. pylori-negative groups during the 12-month study period. Life tables revealed no statistical difference between the 2 H. pylori-positive groups (log rank test, P = 0.84) or between the 3 groups (log rank test, P = 0.94) in the time to first relapse. Two patients in each group developed grade B esophagitis at 12 months.


CONCLUSIONS
H. pylori eradication therapy does not seem to influence relapse rates in GERD patients.
Moayyedi
P
P
The General Infirmary at Leeds, West Yorkshire, England. p.moayyedi@bham.ac.uk
Bardhan
C
C
Young
L
L
Dixon
M F
MF
Brown
L
L
Axon
A T
AT
D000328:Adult; D000368:Aged; D017291:Clarithromycin / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D005764:Gastroesophageal Reflux / Q000209:etiology*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage; D011446:Prospective Studies; D012008:Recurrence; D014011:Tinidazole / Q000008:administration & dosage
D014011:Tinidazole; D017291:Clarithromycin; D009853:Omeprazole